New Meds and Tech

New Drugs and Therapeutics Update CRENESSITY (crinecerfont) capsules and oral solution On December 13, 2024, the FDA approved CRENESSITYTM (crinecerfont) as adjunctive treatment to glucocorticoid replacement…

New Device Announcement. The twiist™ Automated Insulin Delivery (AID) system has received clearance from FDA 510(k), although the launch date is unclear. This insulin pump has…

Generic Victoza® Teva pharmaceuticals launched a generic version of Victoza® (liraglutide injection 1.8mg ) The generic will cost $469.60 for a pack of two pens and…

In March 2023, the FDA extended the approval of Evinacumab (EVKEEZA©) to children 5-11 years with familial homozygous hypercholesteremia. Evinacumab had been previously approved for 12…

US FDA-approval of VAMOROLONE for Duchenne Muscular Dystrophy (DMD)*-a novel alternative steroid with unique properties. New Drugs and Therapeutics   On October 26, 2023, the US…

LUPRON DEPOT-PED 45 mg for 6 months Prepared and edited on behalf of the PES Drug & Therapeutics committee: Shilpa Mehta, MD, Amit Lahoti, MD, Aditi…

New Drugs and Therapeutics Update – NGENLA By Dania Al-Hamad, MD, and Christine Yu, MD   NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog, was approved…

Brief Therapeutic Update from PES Drugs and Therapeutics Committee Jardiance® (empagliflozin) and Synjardy® (empagliflozin and metformin hydrochlorothiazide)   Jardiance® (empagliflozin) and Synjardy® (empagliflozin and metformin hydrochlorothiazide)…

New Meds and Tech from PES Drugs and Therapeutics committee Palovarotene (SohonosTM – Ipsen Pharmaceuticals Inc.) By: Ambika Ashraf, MD and Anna Ryabets-Lienhard, DO   Update:…

Brief Therapeutic Update from PES Drugs and Therapeutics Committee iLet ® Bionic Pancreas   On May 19, 2023, the U.S. Food and Drug Administration approved the…